No Data
No Data
No Data
No Data
No Data
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below summarizes their recent ra
BenzingaApr 24 02:00
ANI Pharmaceuticals Price Target Maintained With a $77.00/Share by Guggenheim
ANI Pharmaceuticals Price Target Maintained With a $77.00/Share by Guggenheim
Dow JonesApr 24 01:04
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $77 Price Target
Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals with a Buy and maintains $77 price target.
Analyst UpgradesApr 24 00:55
ANI Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 17.34% Guggenheim → $77 Reiterates Buy → Buy 03/15/2024 — Capital One Initiates Coverage On →
BenzingaApr 24 00:53
ANI Pharmaceuticals(ANIP.US) Officer Sells US$1.77 Million in Common Stock
$ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy sold 27,232 shares of common stock on Apr 18, 19, 2024 at an average price of $65.1 for a total value of $1.77 million.Source: Announcement W
Futu NewsApr 23 07:10
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 1.1 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 19, $ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy intends to sell 16,809 shares of its common stock on Apr 19, with a total market value of approximately $1.1
Futu NewsApr 20 04:47
No Data
No Data